tebnow
Pharma & Medications/Fierce Pharma

FDA's CNPV Program Faces Mixed Reactions at First Public Hearing

The FDA's inaugural public hearing regarding the Commissioner’s National Priority Voucher (CNPV) pilot program took place on Thursday, drawing a diverse array of opinions from industry stakeholders and healthcare experts. While some industry representatives expressed support for the initiative, which aims to incentivize the development of treatments for neglected diseases, experts voiced significant concerns regarding its potential implications for drug approval processes and public health outcomes. The CNPV program, introduced under the leadership of former FDA Commissioner Marty Makary, is designed to expedite the development of therapies for conditions that lack sufficient market incentives. However, critics argue that it may prioritize profit over patient safety and efficacy. The hearing highlighted the need for a balanced approach that considers both innovation and the rigorous standards of drug evaluation. As the FDA moves forward, the agency will need to address these concerns to ensure that the CNPV program meets its intended goals without compromising public trust or safety.

FDA / CNPV / public hearing / drug development / healthcare policy

Health Tech

All →

Ascension Completes $3.9 Billion AmSurg Acquisition After FTC Mandates Divestitures

Ascension has finalized its $3.9 billion acquisition of AmSurg, an ambulatory surgery provider, following a deal with the Federal Trade Commission (FTC) that required the nonprofit health system to divest seven AmSurg facilities in overlapping markets. This acquisition is part of Ascension's strategy to enhance its outpatient services, reflecting a broader trend among healthcare providers to shift focus from inpatient to outpatient care amid rising costs and regulatory pressures. With this acquisition, Ascension now operates 300 ambulatory surgery centers across 35 states, significantly expanding its footprint in the outpatient sector. The FTC's intervention was prompted by concerns that the merger could lead to increased healthcare prices due to the overlap in services provided by both organizations. To address these concerns, Ascension agreed to divest facilities located in Tennessee, Florida, Oklahoma, Texas, and Kansas, ensuring compliance with antitrust regulations. The FTC will also appoint a monitor to oversee the divestiture process, which Ascension has accepted as part of the agreement. Ascension's CEO, Eduardo Conrado, expressed optimism about the acquisition, stating it positions the health system to move beyond traditional hospital settings and better serve patients through outpatient care. This strategic shift aligns with the growing demand for lower-cost, accessible healthcare options, particularly in the wake of the COVID-19 pandemic, which has accelerated the transition to outpatient services. As the healthcare landscape continues to evolve, this acquisition may set a precedent for future mergers and acquisitions in the industry.

Healthcare Dive · 16h ago

Disease & Epidemiology

All →

CDC Warns Ebola Outbreak in Central Africa Could Exceed 20,000 Cases Without Urgent Action

The Centers for Disease Control and Prevention (CDC) has issued a stark warning regarding the ongoing Ebola outbreak in Central Africa, projecting that the number of cases could escalate to 20,000 or more if immediate and effective public health measures are not implemented. Current data indicates approximately 400 confirmed cases and 63 deaths, but experts believe the actual numbers may be higher due to unreported infections. The CDC's modeling suggests that without strong interventions, the outbreak could mirror the catastrophic West Africa epidemic of 2014-2016, which resulted in over 28,000 cases and more than 11,000 fatalities. Satish Pillai, the CDC's incident manager for the Ebola response, emphasized the urgency of the situation, stating that the outbreak is on a dangerous trajectory. Jennifer Nuzzo from Brown University cautioned that while the modeling provides insight, predicting the exact progression of outbreaks is challenging due to limited data. The outbreak has been complicated by ongoing armed conflict in the region, which has led to significant population displacement and hindered response efforts. The World Health Organization declared the outbreak a global health emergency in May, highlighting the need for immediate action. The CDC's projections are based on various scenarios, including the effectiveness of isolation measures for infected individuals. If isolation rates improve significantly, the number of cases could be reduced to around 10,000. However, if the death toll is underestimated, the situation could worsen. Despite the alarming situation in Central Africa, experts believe the risk of the outbreak spreading to the United States remains low, thanks to stringent travel restrictions and health screenings for travelers from affected regions. The CDC continues to monitor the situation closely and is preparing for various potential outcomes as the response evolves.

STAT News · 8h ago

Highlights from the American Diabetes Association Conference: GLP-1s and Research Funding Concerns

The American Diabetes Association (ADA) annual conference in New Orleans has sparked significant discussions among healthcare professionals regarding the latest advancements in diabetes treatment, particularly the newer GLP-1 receptor agonists. These medications have shown promise in managing blood glucose levels and aiding weight loss, which is crucial for diabetes management. However, the conference also highlighted concerns about potential cuts to diabetes research funding, as voiced by Rick Woychik, a senior adviser at the NIH. His remarks underscore the importance of sustained investment in diabetes research to continue developing effective treatments and understanding the disease better. The implications of these discussions are far-reaching, affecting not only researchers and healthcare providers but also the millions of individuals living with diabetes. The advancements in GLP-1 therapies could lead to improved patient outcomes, but the potential reduction in research funding raises alarms about the future of diabetes innovation. Attendees at the conference are urged to advocate for continued support for diabetes research to ensure that progress is not hindered. As the conference unfolds, further insights and updates are expected, particularly regarding the latest clinical data on GLP-1s and ongoing debates about research funding. The ADA conference serves as a critical platform for sharing knowledge and shaping the future of diabetes care, making it essential for healthcare professionals to stay informed and engaged in these discussions.

STAT News · 9h ago

Federal Workers at HHS Face Job Security Risks Amid New Executive Order

An executive order issued by President Trump has reclassified approximately 8,000 employees within the Health and Human Services (HHS) Department, making it easier for them to be dismissed. This change affects key personnel involved in shaping health policy, managing federal health insurance programs, and overseeing health data privacy. The reclassification, part of a broader initiative known as 'Schedule F,' aims to create a workforce that is less insulated from political pressures, thereby increasing the influence of the executive branch over health policy decisions. Experts in health policy express concern that this shift could undermine the integrity of public health initiatives and grant oversight, particularly at agencies like the National Institutes of Health (NIH). As these changes take effect, the implications for public health governance and the potential for increased political interference in health-related decisions are significant, raising questions about the future of federal health programs and the protection of health data privacy. Stakeholders in the healthcare sector are urged to monitor these developments closely as they may impact the operational landscape of federal health services.

STAT News · 10h ago

Pharma & Medications

All →

FDA's CNPV Program Faces Mixed Reactions at First Public Hearing

The FDA's inaugural public hearing regarding the Commissioner’s National Priority Voucher (CNPV) pilot program took place on Thursday, drawing a diverse array of opinions from industry stakeholders and healthcare experts. While some industry representatives expressed support for the initiative, which aims to incentivize the development of treatments for neglected diseases, experts voiced significant concerns regarding its potential implications for drug approval processes and public health outcomes. The CNPV program, introduced under the leadership of former FDA Commissioner Marty Makary, is designed to expedite the development of therapies for conditions that lack sufficient market incentives. However, critics argue that it may prioritize profit over patient safety and efficacy. The hearing highlighted the need for a balanced approach that considers both innovation and the rigorous standards of drug evaluation. As the FDA moves forward, the agency will need to address these concerns to ensure that the CNPV program meets its intended goals without compromising public trust or safety.

Fierce Pharma

Clinical Research

All →

Finerenone Shows Promise as Foundational Therapy for Chronic Kidney Disease

A recent pooled analysis of individual participant data has demonstrated that finerenone significantly reduces the risk of progression in chronic kidney disease (CKD), including instances of kidney failure. Additionally, the drug has been shown to lower rates of heart failure hospitalizations, cardiovascular deaths, and all-cause mortality among CKD patients. These findings are crucial as they suggest that finerenone could serve as a foundational therapy for CKD, applicable to a diverse range of patients regardless of the underlying causes of their disease, levels of glycaemia, estimated glomerular filtration rate (eGFR), or albuminuria levels. The implications of this research are substantial, as it may lead to changes in treatment protocols for CKD, potentially improving patient outcomes and reducing healthcare burdens associated with advanced kidney disease. As the medical community continues to evaluate the role of finerenone, further studies may be necessary to solidify its position in CKD management.

The Lancet · 20h ago

Health Policy

All →

Immigrant Detainees Report Alarming Medical Neglect Amid Rising Custody Numbers

As the U.S. Immigration and Customs Enforcement (ICE) detains over 75,000 immigrants, reports of medical neglect have surged. A collaborative investigation by KFF Health News and The Associated Press reveals that hundreds of detainees across at least 33 states have reported inadequate medical care, including delays in receiving medications for chronic conditions such as diabetes, Parkinson's disease, and HIV. Court filings indicate that detainees have experienced severe health consequences, including untreated infections, untreated cancers, and even strokes due to lack of timely medical attention. The investigation utilized a national network of volunteers to gather court records, uncovering a troubling pattern of medical neglect within ICE facilities. Detainees described waiting weeks for medical assistance, leading to deteriorating health conditions. One detainee suffered a stroke during a video call with his daughter, while another faced potential amputation due to an untreated leg infection. These accounts highlight the urgent need for oversight and accountability in the healthcare provided to individuals in ICE custody. Families of detainees express their anguish as they witness their loved ones' health decline, fearing for their safety amid a rising death toll that has reached 51 since the beginning of the current administration. Despite claims from the Department of Homeland Security (DHS) that detainees receive timely medical care, the reality on the ground suggests a significant gap between policy and practice. As scrutiny increases, the future of medical care for detainees remains uncertain, raising critical questions about the responsibilities of ICE and the DHS in safeguarding the health of vulnerable populations.

KFF Health News · 12h ago

New Billing Codes for Maternity Care May Increase Costs for Expectant Families

Starting January, new billing codes will change how maternity care is billed in the U.S., shifting from a bundled payment model to a fee-for-service approach. This change, advocated by the American College of Obstetricians & Gynecologists (ACOG), aims to better reflect the diverse and complex needs of expectant mothers, who often require varying levels of care. The new system allows for more individualized billing based on the actual services provided, which could include more or fewer prenatal visits depending on patient needs. While OB-GYNs support this transition, concerns arise regarding potential increases in out-of-pocket costs for patients, particularly those with high-deductible health plans. Experts warn that the new billing structure may lead to more line items on bills, raising questions about how these costs will be passed on to families. The implementation of these codes is also under scrutiny, with insurance representatives expressing worries about the operational changes required to adapt to the new system. The Centers for Medicare & Medicaid Services (CMS) is currently reviewing the proposed coding changes, and the outcome will significantly impact how maternity services are reimbursed. Although federal law mandates that certain preventive maternity services be provided at no cost, the shift to fee-for-service billing raises concerns about incentivizing unnecessary procedures, which could ultimately affect the quality of care. As the healthcare community prepares for these changes, the focus remains on ensuring that the new billing practices do not compromise care quality or accessibility for expectant families. Stakeholders are urged to monitor the implementation closely to mitigate any adverse effects on patient costs and care outcomes.

KFF Health News · 21h ago

Over 2 Million Children Risk Losing Health Insurance Amid GOP Cuts and Policy Changes

Since the beginning of the Trump administration in 2025, over 1 million children have lost their health insurance, with projections indicating that an additional million could follow due to recent immigration policies and new Medicaid eligibility criteria. The significant cuts to federal healthcare programs, particularly through the Republicans' One Big Beautiful Bill Act, have led to increased health insurance premiums and widespread confusion regarding coverage eligibility. This has resulted in a notable decline in enrollment in both Affordable Care Act (ACA) plans and Medicaid, leaving nearly 2 million children uninsured, as reported by the Georgetown University McCourt School of Public Policy’s Center for Children and Families. The implications of these changes are profound, particularly for vulnerable populations who rely on these programs for essential healthcare services. The fear and uncertainty surrounding the new rules complicate access to health coverage, as highlighted by KFF Health News chief Washington correspondent Julie Rovner during her appearance on WAMU’s Health Hub. The ongoing situation raises concerns about the affordability of health insurance for American families, especially as they face rising costs and potential loss of coverage. As the healthcare landscape continues to evolve, stakeholders are urged to monitor these developments closely. The potential for millions of children to remain uninsured poses significant public health challenges and could lead to increased healthcare costs for families and the system as a whole. Policymakers and healthcare providers must address these issues to ensure that vulnerable populations receive the necessary support and coverage moving forward.

KFF Health News · 21h ago

Nutrition & Prevention

All →

Ebola Outbreak Update: CDC Reports on DRC and Uganda's Situation and U.S. Risk Assessment

The Centers for Disease Control and Prevention (CDC) has released new reports detailing the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda, marking the 17th outbreak in DRC. The outbreak, which began among healthcare workers, has escalated to the largest Bundibugyo outbreak on record, exacerbated by existing conflicts and limited healthcare access in the affected regions. The CDC emphasizes the need for sustained resources and attention to control the outbreak effectively. Despite the serious nature of the outbreak, the CDC assesses that the risk to the general public in the United States remains low. Current modeling indicates a low likelihood of Ebola being imported into the U.S., and even if a case were to occur, the risk of secondary transmission is minimal due to robust public health measures in place. The CDC has implemented entry restrictions and health screenings at four major airports to mitigate the risk of importation. The CDC's reports also include modeling scenarios to help public health officials prepare for potential future developments in the outbreak. These scenarios serve as planning tools rather than predictions, highlighting the importance of urgent action to prevent the outbreak from escalating to levels seen during the 2014-2016 West Africa outbreak. The CDC will continue to monitor the situation and update its assessments as necessary, reinforcing the need for vigilance in public health responses.

CDC Healthy Living · 8h ago